Our CEO, Dr David Solomon, recently spoke with BioHub about our differentiated RNA therapeutics strategy, and the significant potential for further innovation in this field. The interview also discusses our dual-target PCSK9 and Lp(a) programme, at a time when interest in genetically targeted therapies for cardiovascular disease continues to grow.